Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs;Papel del citocromo P450 en la farmacocinética y en la farmacogenética de los fármacos antihipertensivos

Farmacia Hospitalaria

Volumn 35, Issue 2, 2011, Pages 84-92

  Rodriguez Arcas M J ^a   Garcia Jimenez E ^a   Martinez Martinez F ^a   Conesa Zamora, P ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b Hospital Universitario Santa Maria del Rosell   (Spain)

Author keywords

Antihypertensive drugs; Cytochrome P450; Pharmacogenetics; Pharmacokinetics; Single nucleotide polymorphism, SNP

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYTOCHROME P450;

DATA BASE; DNA POLYMORPHISM; DRUG METABOLISM; GENE FREQUENCY; INDIVIDUALITY; PHARMACOGENETICS; REVIEW;

EID: 79952739657     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farma.2010.05.006     Document Type: Short Survey

References (61)

1. American Pharmacists Association; National Association of Chain Drugs Stores Foundation. Medication Therapy Management in community pharmacy practice: core elements of an MTM service. J Am Pharm Assoc. 2005;45:573-9.
2. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-56. (Pubitemid 32201949)
3. Parody Rúa E, Segu Tolosa J. Efectividad y estimación de costes en una intervención sobre problemas relacionados con los medicamentos en atención primaria. Aten Primaria. 2005;35:472-7. (Pubitemid 40895985)
4. Materson BJ. Variability in response to antihypertensive drugs. Am J Med. 2007;120:S10-20.
5. Mathews CK, van Holde KE, Ahern KG, editors. Bioquímica. 3a Edición Madrid: Pearson Educación, SA; 2002.
6. Humma LM, Terra SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am J Health Syst Pharm. 2002;59: 1241-52. (Pubitemid 34747462)
7. National Center for Biotechnology Information. US National Library of Medicine. National Institutes of Health. Bethesda (USA): [citado 12-12-2009]. Disponible en: www.ncbi.nlm.nih.gov.
8. European Molecular Biology Laboratory (EMBL), Wellcome Trust Sanger Institute (WTSI). Cambridge (Reino Unido): [citado 12-12-2009]. Disponible en: www.ensembl.org.
9. Tufts University Homepage. Michael H Court. Department of Pharmacology and Experimental Therapeutics. Tufts University. Boston (USA): [citado 12-01-2010]. Disponible en: www.tufts.edu.
10. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm. 2002;59:2061-9. (Pubitemid 35257727)
11. Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetic of cardiovascular drug. Clin Chim Acta. 2007;381:26-31.
12. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 y CYP2D6 in an Italian population. Pharmacol Res. 2004;50:195-200.
13. Chialda L, Griffith LS, Heinig A, Pahl A. Prospective use of CYP pharmacogenetics and medication analysis to facilitate improved therapy- a pilot study. Per Med. 2008;5:37-45.
14. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45:525-38. (Pubitemid 28270907)
15. Pharmacogenomics Knowledge Base. [Base de datos en Internet]. National Institutes of Health, National Institute of General Sciences. Stanford (USA): [citado 12-12-2009]. Stanford University. Disponible en: www.pharmgkb.org.
16. Entrez SNP [Base de datos en Internet]. Bethesda (USA): National Center for Biotechnology Information. US National Library of Medicine. National Institutes of Health. [citado 12-12-2009]. Disponible en: www.ncbi.nlm.nih.gov/ projects/SNP.
17. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Ingelman-Sundberg M, Daly AK, Nebert DW aditores. [citado 12-12-2009]. Disponible en: www.cypalleles.ki.se.
18. Kim YM, Yoo SH, Kang RY, Kim MJ, Bae YY, Lee YK. Identifiying drugs needing pharmacogenetic monitoring in a korean hospital. Am J Health Syst Pharm. 2007;64:166-75. (Pubitemid 46395690)
19. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A. Genetic polymorphism of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 y CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007;21:419-26. (Pubitemid 47084032)
20. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphism in Portugal. Pharmacogenomics. 2007;8:703-12.
21. Menoyo A, del Río E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct. 2006;24:381-5. (Pubitemid 44379576)
22. Crecenti A, Mas S, Gassó P, Baiget M, Bernardo M, Lafuente A. Simultaneous genotyping of CYP2D6 *3, *4, *5 y *6 polymorphisms in a Spanish population trough multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clin Exp Pharmacol Physiol. 2007;34:992-7.
23. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol. 2006;44:107-18. (Pubitemid 43082210)
24. Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007;29:412-6. (Pubitemid 47220457)
25. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005;6:19.
26. García-Martín E, Martínez C, Pizarro RM, García-Gamito FJ, Gullsten H, Raunio H. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71:196-204. (Pubitemid 34271123)
27. Correia C, Santos P, Coutinho AM, Vicente AM. Characterization of pharmacogenetically relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample. Cell Biochem Funct. 2009;27:251-5.
28. Monografía Labetalol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 01-04-2008]. Disponible en: www.rxlist.com.
29. Monografía Metoprolol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 21-08-2007]. Disponible en: www.rxlist.com.
30. Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998;87:289-94. (Pubitemid 28204580)
31. Monografía Atenolol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 15-08-2008]. Disponible en: www.rxlist.com.
32. Lija JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmackinetics of acebutolol. Br J Clin Pharmacol. 2005;60:659-63. (Pubitemid 41705387)
33. Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53:814-22.
34. Monografía Esmolol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 05-10-2007]. Disponible en: www.rxlist.com.
35. Monografía Nadolol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 20-03-2008]. Disponible en: www.rxlist.com.
36. Tsikouris JP, Cox CD. A review of class III antiarrhythmic agents for auricular fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy. 2001;21:1514-29. (Pubitemid 33117254)
37. Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther. 2009;85:269-72.
38. Monografía Propranolol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 20-02-2008]. Disponible en: www.rxlist.com.
39. Bijl MJ, Visser LE, van Schaik RH, Kors JA,Witteman JC, Hofman A. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009;85:45-50.
40. Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005;78:378-87. (Pubitemid 41393673)
41. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874-87.
42. Scheen AJ. Pharma-clinics medication of the month. Nebivolol (Nobiten). Rev Med Liege. 2001;56:788-91.
43. Wojciechowski D, Papademetriou V. Beta-blockers in the management of hypertension: focus on nebivolol. Expert Rev Cardiovasc Ther. 2008;6:471-9.
44. Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007;63:575-82. (Pubitemid 46632567)
45. Monografía Carvedilol. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 11-07-2009]. Disponible en: www.rxlist.com.
46. Minushkina LO, Zateǐshchikova AA, Zateǐshchikov DA, Mankhaeva BB, Savel'eva EG, Kochkina MS. Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension. Kardiologiia. 2008;48:20-6.
47. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843-52. (Pubitemid 30201767)
48. Monografía Nimodipino. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 14-09-2008]. Disponible en: www.rxlist.com.
49. Monografía Verapamilo. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 07-04-2009]. Disponible en: www.rxlist.com.
50. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther. 2006;80:646-56. (Pubitemid 44920220)
51. Bhatnagar V, García EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, et al., AASK Study Investigators. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95-103. Epub 2009 Nov 12.
52. Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007;81(3):386-91. (Pubitemid 46364490)
53. Monografía Lisinopril. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 09-12-2008]. Disponible en: www.rxlist.com.
54. Barkin RL, Barkin D. Pharmacologic management of acute and chronic pain: focus on drug interactions and patientspecific pharmacotherapeutic selection. South Med J. 2001;94: 756-70.
55. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de medicamentos. Colección Consejo Plus 2008. Madrid (España); 2008.
56. Monografías del Candesartán, Telmisartán, Doxazosina, Prazosina e Hidroclorotiazida. RxList, the internet drug index. [Base de datos en Internet]. WebMD network. San Clemente (USA): [citado 28-04-2009]. Disponible en: www.rxlist.com.
57. Kusama M, Maeda K, Chiba K, Aoyama A, Sugiyama Y. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm Res. 2009;26:822-35.
58. Monografía Espironolactona. RxList, the Internet drug index. [Base de datos en internet]. WebMD network. San Clemente (USA): [citado 10-05-2008]. Disponible en: www.rxlist.com.
59. Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther. 2004;76:557-66. (Pubitemid 39610484)
60. Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet. 2008;47:323-32. (Pubitemid 351508118)
61. Marteau JB, Gambier N, Jeannesson E, Siest G, Visvikis-Siest S. Pharmacogenomics and antihypertensive drugs: a path towards personalized medicine. Per Med. 2007;4:393-412. (Pubitemid 350303098)